English 
Română (Romanian)
Deutsch (German)
Français (French)- Nederlands (Dutch)
- Polski (Polish)
- Svenska (Swedish)
- Dansk (Danish)
- Norsk bokmål (Norwegian Bokmål)
- Ελληνικά (Greek)
- Čeština (Czech)
- Slovenčina (Slovak)
- Slovenščina (Slovenian)
- Hrvatski (Croatian)
- Eesti (Estonian)
- Latviešu (Latvian)
- Lietuvių (Lithuanian)
- Português (Portuguese (Portugal))
- Español (Spanish)
- हिन्दी (Hindi)
- Türkçe (Turkish)
- Русский (Russian)
- 日本語 (Japanese)
- 简体中文 (Chinese (Simplified))
News :
Impact of Hyperthermia on Quality of Life (QoL): Pain Relief, Fatigue Reduction, and Adjuvant Immunological Benefits Hyperthermia and Survival of Cancer Patients: Clinical Evidence Demonstrating an Increase in Overall Survival (OS) by Over 50% Therapeutic Integration of Hyperthermia in Modern Oncology: A Critical Analysis of Phase III Trials and Meta-Analyses (OS, DFS, CR Endpoints) Quasi feasibility study(case control) associating deep local hyperthermia treatment with standard cancer treatments and describing patterns of response ESHO Preliminary results of chemoradiation plus hyperthermia and high dose rate brachytherapy for locally advanced cervical carcinoma ESHO
Andromedic HyDeep 600 WM: Advanced Oncological Hyperthermia for Enhanced Cancer Treatment
Andromedic HyDeep 600 WM:
Advanced Oncological Hyperthermia DEVICE
Improve the Clinical Results of Your Cancer Treatments for Your Patients
Are you seeking a clinically validated method to enhance cancer treatment outcomes? Andromedic Srl is a market leader and a key player worldwide in the electromedical devices sector, specialized in creating deep capacitive oncological RF-hyperthermia equipment with advanced modulated RF Radio Frequency, capable of generating high-intensity electromagnetic pulses. Andromedic’s advanced modulated RF Hyperthermia devices, including the HyDeep 600 WM, deliver selective local hyperthermic, electromagnetic, and bioresonant effects. Experience significant benefits: improved Overall Survival, enhanced Local Tumor Control, and a superior Quality of Life.
FDA Approval
Hyperthermia has been successfully utilized in oncological patient treatment and received FDA approval over 35 years ago. In the USA, the Scientific Society of Thermal Medicine, comprising leading North American experts in hyperthermia, was established. Various centers and organizations, including the National Cancer Institute (NCI), the American Cancer Society, and the FDA, are actively considering the use of hyperthermia in tumor treatment.
ESHO & ASHO
Similarly, in Asia, the Asian Society for Hyperthermic Oncology (ASHO) exists, and in Europe, the European Society for Hyperthermic Oncology (ESHO) unites centers dedicated to hyperthermia, adhering to international guidelines.
Clinical Evidence
Hundreds of clinical trials on hyperthermia have been published.
Abundant Level 1A evidence from phase III clinical trials support the benefits of hyperthermia in Oncology.
Investigations consistently demonstrate significantly higher complete remission rates when chemoradiotherapy is combined with hyperthermia compared to chemoradiotherapy alone.
Introducing the Andromedic HyDeep 600 WM:
A Leap in Oncological Hyperthermia Devices
Advanced local oncologic RF hyperthermia device Andromedic HY DEEP 600WM
HyDeep 600 WM: Professional Modulated RF-Hyperthermia Device
Designed for hospitals and medical centers, the HyDeep 600 WM is a deep capacitive oncological device utilizing 13.56 MHz RF with ASK (Amplitude-Shift Keying) modulation in OOK (ON-OFF Keying) mode.
TMS Protocol (Thermal Modulation System)
Technologically more advanced than random noise protocols, our TMS protocol allows for high-intensity electromagnetic pulses that prevent cancer cell adaptation while sparing healthy tissues.
Key Features & Capabilities:
- Specific RF Protocols: Tailored for each cancer type, adjusted by height, weight, and electrode distance.
- Versatile Treatment: Effective for both deep and shallow tumors, as well as some non-oncological pathologies (e.g., benign tumors, Lyme disease pain, inflammation, pancreatitis).
- 38.4 cm Penetration: Superior deep-tissue reach compared to standard 8MHz cCHT hyperthermia devices.
- High-Intensity Electromagnetic Pulses: Amplifies biological effects and transmits bio-information to tissues.
- Combined Synergy: Simultaneous local hyperthermia, selective electromagnetic impact, and bioresonant effects.
Biological Synergy & Results:
Immune System Activation:
- TME Modulation: Induces Immunogenic Cell Death (ICD) (ref).
- Cytokine Release: Stimulates leukocyte arrival at the heated tumor area.
- Pathogen Targeting: Resonance-specific amplification against viruses and bacteria.
The Andromedic HyDeep 600WM modulated hyperthermia device has been successfully utilized in clinical studies and hospitals across Europe (Italy, Spain).
Clinically Proven Benefits of Modulated RF Hyperthermia
Chemosensitization & Enhanced Perfusion
mHT optimizes drug pharmacokinetics and acts as a powerful chemosensitizer. Due to the thermally induced vasodilation effect, it increases vascular perfusion & alters tumor cell membrane permeability. This leads to enhanced cellular uptake and improved delivery of chemotherapeutic substances deep into the necrotic tumor core, demonstrating significant synergistic effects with standard oncological treatments.[1]
Radiosensitization & Hypoxia Reduction
mHT is a highly potent radiosensitizer that directly addresses radiotherapy failure. It enhances outcomes by inducing localized vasodilation to improve tissue oxygenation. This physiological shift significantly reduces the hypoxic fraction of the tumor, a microenvironment typically resistant to ionizing radiation. Furthermore, thermal stress inhibits the intracellular repair mechanisms of radiation-damaged DNA, ensuring more efficient cell death.[1]
Survival Gains in Refractory Tumors
Phase II clinical data demonstrates significant survival extensions (Level 2 Evidence) for tumors historically resistant to standard treatments.
For Glioblastoma (GBM), combining mHT with the Stupp protocol increased the 1-year survival rate from ~37% to 73%.[2]
In Pancreatic Cancer, integrated thermochemotherapy extended median Overall Survival (OS) to approximately 20 months, compared to roughly 9 months for standard chemotherapy alone.[3]
Immunotherapy & Systemic Abscopal Effect
Hyperthermia modulates the anti-tumor immune response, effectively transforming immunologically “cold” (non-inflamed) tumors into “hot” (inflamed) immunogenic targets. The application of heat induces an in situ tumor vaccine effect through the release of tumor antigens and Heat Shock Proteins (HSPs), notably HSP70. These HSPs act as critical danger signals that facilitate antigen uptake by dendritic cells (DCs). Ultimately, this immune activation cascade leads to increased tumor cell lysis mediated by Natural Killer (NK) cells and CD8+ T cells. This systemic immunomodulation provides a strong biological rationale for the abscopal effect and therapeutic synergy with Immune Checkpoint Inhibitors.[4][5]
“In gastrointestinal cancers, mHT has been proven superior to nivolumab, ipilimumab, and interleukin 2 by Ralph Kleef et al.” [6]
Increased Overall Survival (OS) & Quality of Life (QoL)
Clinical studies consistently demonstrate increased Overall Survival in cancer patients with the addition of mHT, alongside significantly improved local tumor control and enhanced Quality of Life.[4] A fundamental driver of improved QoL is the superior disease control achieved through multimodal integration. By enhancing the efficacy of radiotherapy and chemotherapy, hyperthermia actively reduces the physical and psychological burden associated with tumor progression and its subsequent complications.
Andromedic Srl: A Legacy of Innovation
Andromedic Srl is a global leader in the hyperthermia medical market, providing the HyDeep 600WM – one of the world’s most technologically advanced local hyperthermia devices.
Andromedic Srl – HT Producer History
Founded in 1994 in Italy by a group of healthcare experts, Andromedic quickly became a powerhouse in technical assistance for electromedical equipment. In 2012, the Oncological Hyperthermia division became Andromedic Srl, focusing exclusively on meeting the global demand for advanced cancer treatment solutions.
Premium Wellness Distrib Srl – Distribuitor Partnership
Premium Wellness Distrib SRL & Romanian Society of Oncologic Hyperthermia are official authorized partners for Andromedic Srl and the von Ardenne Institute.
Our team members have been integrating mHT as well as WBH wiRA with conventional & integrative cancer treatments since 2017.
Meet Our Experts
Trained & Certified by the President of the German Society for Hyperthermia
Founders of SRHO( Romanian Society Oncological Hyperthermia), members of ESHO , partners of DGHT eV and SIIO
Contact Us
Your Partner in Advanced Hyperthermia Solutions
Whether you are looking for a clinical partnership, technical specifications, or a personalized hyperthermia device price quote for your medical center, our leadership team is available for direct consultation.
Premium Wellness Distrib SRL – Official Authorized Partner
Dedicated to improving cancer treatment outcomes through modulated RF-Hyperthermia.
Clinical References & Bibliography
- Lee SY, et al. “Current understanding of modulated electro-hyperthermia in cancer treatment.” Kosin Medical Journal (2024). View Study
- Fiorentini G, Sarti D, et al. “Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study.” Frontiers in Oncology (2019).
- Fiorentini G, Sarti D, et al. “Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study.” World Journal of Clinical Oncology (2023).
- Abreu MM, et al. “From cold to hot: mechanisms of hyperthermia in modulating tumor immunology for enhanced immunotherapy.” MDPI Cancers. View Study
- Research regarding systemic abscopal effect, immunomodulation and hyperthermia. NCBI/PMC. View Study
- Kleef R, et al. “Fever-range whole-body hyperthermia combined with immunotherapy.” NCBI/PMC. View Study